Codexis (0I0X) AI Stock Analysis
Codexis
(LSE:0I0X)
No summary available
Codexis (0I0X) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $130.31M
- Dividend Yield
- ―
- Average Volume (3M)
- 10.04K
- Price to Earnings (P/E)
- -3.5
- Beta (1Y)
- 0.49
- Revenue Growth
- 35.89%
- EPS Growth
- 58.70%
- Country
- UK
- Employees
- 146
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Codexis Business Overview & Revenue Model
Company Description
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemi...
Codexis Earnings Call Summary
The call presents a predominantly positive strategic and technical narrative: clear technology milestones (stereochemistry control, Starterless initiation), progressing scale demonstrations (hundreds of grams toward kilogram scale), active CDMO and biopharma engagements, improving product gross margin (73%) and disciplined expense reductions. Financially, the company showed a modest year-over-year revenue decline in the quarter, a pre-financing drop in cash balance, and an ongoing net loss. These negatives are mitigated by a successful $25M financing that restores pro forma cash to ~$79.8M and management's stated cash runway through 2028, plus reiterated 2026 revenue guidance ($70M–$76M). The primary remaining risks are revenue lumpiness, the need to convert pilot/tech-transfer activity into firm commercial contracts, and successfully industrializing ECOsynthesis at commercial scale. On balance, highlights (technical differentiation, commercial engagement, margin improvement, financing and runway) outweigh the lowlights (quarterly revenue decline, cash drawdown prior to financing, execution risk), supporting a constructive view of progress and prospects.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Codexis reiterated 2026 revenue guidance of $70–$76 million (expected to be back‑half weighted) after reporting Q2 revenue of $14.9M (vs. $15.3M year‑ago) and a Q2 product gross margin of 73% (management expects full‑year gross margins to improve into the high‑60s); Q2 R&D was $11.7M and SG&A $10.9M, with a net loss of $12.0M (vs. $13.3M). The company ended Q2 with $54.9M in cash and, following a $25M net equity financing, a pro‑forma cash balance of ~ $79.8M that management says funds operations and capex through 2028 (including ~ $25M of planned GMP facility construction); operational milestones include advancing ECOsynthesis to hundreds of grams today, a 500‑gram pilot target in the Eco Innovation Lab, a goal of kilogram‑scale prior to GMP start, completion of small‑scale tech transfers with three CDMOs (one in advanced long‑term commercial negotiations), supporting 14 commercial enzyme‑dependent products (four approvals in 2026 and one label expansion), 15 programs in Phase II/III with seven readouts expected in the next two years, and broader industry context of an expected ~30‑fold increase in siRNA demand by 2035 and an estimated ~70% capital efficiency advantage for ECOsynthesis.
Codexis Risk Analysis
Codexis disclosed 50 risk factors in its most recent earnings report. Codexis reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksCodexis Peers Comparison
Overall Rating
CGEN65Neutral
MXCT56Neutral
CBUS50Neutral
DTIL43Neutral
ADAG41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CGEN | 65Neutral | $187.56M | 5.27 | 42.57% | ― | 234.18% | ― |
| MXCT | 56Neutral | $164.10M | -4.76 | -21.01% | ― | -13.15% | 21.12% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CBUS | 50Neutral | $98.59M | -0.78 | -320.60% | ― | -10.30% | 84.17% |
| DTIL | 43Neutral | $194.87M | -2.53 | -91.60% | ― | 3472.96% | 67.74% |
| ADAG | 41Neutral | $168.53M | -5.32 | -29.09% | ― | 8906.15% | 41.48% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0I0X | Codexis | 1.19 | -1.04 | -46.64% | |
| CGEN | Compugen | 1.98 | 0.25 | 14.45% | |
| MXCT | MaxCyte, Inc. | 1.59 | -0.02 | -1.24% | |
| CBUS | Cibus, Inc. | 1.29 | -0.15 | -10.42% | |
| DTIL | Precision Biosciences | 7.06 | -0.30 | -4.08% | |
| ADAG | Adagene, Inc. | 2.51 | 0.72 | 40.22% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.